rethinkTHC Search
Menu
Make room for a better question

Research library — page 133

Browse more cannabis research, findings, methods, and limitations.

Filter by topic, method, and evidence

You can select more than one topic or evidence level.

Clear filters

2008 / Experimental (In Vitro + In Vivo) / Strong (S Tier Landmark) evidence

The terpene in black pepper that is literally a cannabinoid ↗

Beta-caryophyllene from black pepper selectively activates the CB2 cannabinoid receptor — the only terpene confirmed to directly bind a cannabinoid receptor, with anti-inflammatory effects proven in mice.

2016 / Narrative Review / Policy Analysis / Moderate — Comprehensive Policy Review Synthesizing Pharmacokinetic Data, ER Statistics, And Regulatory Frameworks evidence

The Edible Safety Report That Changed Cannabis Regulation ↗

The comprehensive RTI review that documented why edibles cause disproportionate ER visits and established the evidence base for the 10mg standard serving size.

2011 / Enriched Enrollment RCT / High evidence

The Trial That Made Cannabis a Real Prescription Medicine ↗

Pivotal Phase III RCT. 572 MS spasticity patients, enriched-enrollment design. 47.6% responded to Sativex in open-label phase. Among randomized responders, Sativex maintained benefit vs placebo deterioration (p=0.0002). Led to approval in 25+ countries.

2019 / Clinical Practice Framework / Expert Review / Expert Opinion + Clinical Practice (A Tier) evidence

The doctor who proved less cannabis works better than more ↗

Based on 18,000+ patients, Sulak showed that most cannabis patients use far more than they need — 1-5mg THC often provides better therapeutic results than higher doses, without tolerance buildup.

2012 / Theoretical Review / Strong — Comprehensive Multi Disciplinary Review Synthesizing Genetic, Neurobiological, Epidemiological, And Evolutionary Evidence From Dozens Of Studies evidence

The Paper That Dismantled the Gateway Theory ↗

The comprehensive review that argued the gateway hypothesis should be replaced by the common liability model: shared genetic and neurobiological risk factors, not cannabis itself, drive drug escalation.

2003 / Twin Study (Cross Sectional) / Strong — Twin Design Controls For Genetic And Shared Environmental Confounds That Plague Observational Studies evidence

The Twin Study That Gave the Gateway Theory Its Strongest Evidence ↗

The Australian twin study that provided the strongest evidence for a cannabis gateway effect: early-using twins were 2-5x more likely to escalate to other drugs.